

Addendum

Addendum: Using cancer proteomics data to identify gene candidates for therapeutic targeting

Diana Monsivais^{1,2,3}, Sydney E. Parks^{1,2,4}, Darshan S. Chandrashekar^{5,6,7}, Sooryanarayana Varambally^{5,6,8} and Chad J. Creighton^{3,9,10}

¹Center for Drug Discovery, Baylor College of Medicine, Houston, TX 77030, USA

²Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA

³Dan L. Duncan Comprehensive Cancer Center Division of Biostatistics, Baylor College of Medicine, Houston, TX 77030, USA

⁴Cancer and Cell Biology Program, Baylor College of Medicine, Houston, TX 77030, USA

⁵O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL 35233, USA

⁶Molecular and Cellular Pathology, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA

⁷Genomic Diagnostics and Bioinformatics, Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35233, USA

⁸The Informatics Institute, University of Alabama at Birmingham, Birmingham, AL 35233, USA

⁹Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA

¹⁰Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA

Published:

Copyright: © 2024 Monsivais et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: This article received a publication fee waiver.

Original article: Oncotarget. 2023; 14:399–412. <https://doi.org/10.18632/oncotarget.28420>